Lucy Burr

A/Prof Lucy Burr is an experienced respiratory physician, training supervisor and clinical trials researcher at Mater Health and Mater Research – University of Queensland (UQ). She has a PhD (2017) in bronchiectasis microbiology and is an Associate Professor at the School of Medicine, UQ. She is the Director of Respiratory, Sleep and Cystic Fibrosis medicine at the Mater Hospital, Brisbane. As well as directing the respiratory clinical service at the Mater, Lucy has an active role in teaching both specialist trainees and medical students. She is a RACP college supervisor and trains one advanced trainee and four basic trainees per year. She directly supervises four medical students in her clinical team per year. Lucy is also currently supervising 5 PhD students, researching diverse fields such as glucose control in cystic fibrosis, asthma, fatigue, IL-22 and the effect of sleep on social cognition. Lucy is recognised nationally for her clinical work on respiratory infections. She is the chair of the Acute and Critical Care panel for the National COVID-19 clinical evidence taskforce and a member of the guideline leadership group. Additionally, she is the recent chair (2020-2022) of the expert reference group on COVID-19 for the Royal Australasian College of Physicians. She is a recent (2019- 2021) convenor of the respiratory infectious disease special interest group of the Thoracic Society of Australia and New Zealand, the Queensland TSANZ branch president and past president (2017-2020), a recent board director of the TSANZ national body and current Chair of the Australian Bronchiectasis Consortium. Lucy is currently serving on the TSANZ annual scientific meeting and World Bronchiectasis conference steering committees. She is recognised internationally for her work on Cystic Fibrosis (top 1.8% expertscape February 2024) and Bronchiectasis (top 2.2% expertscape February 2024) and has published in high impact clinical journals including the New England Journal of Medicine and the Lancet Respiratory Medicine, across a range of respiratory and infectious disease subjects, with >1500 citations in the past 5 years. In addition to her clinical work, Lucy is the custodian and manager of the David Serisier Research biobank at Mater Research, a clinical repository of human samples from patients living with respiratory diseases. Lucy is also an experienced principal investigator on many pharmaceutical studies ranging from phase 1b to phase 4 studies investigating therapeutics for CF, IPF, COPD, COVID, influenza pulmonary hypertension and bronchiectasis. She has designed and lead non-pharmaceutical interventional studies investigating the role of macrolide in modulating inflammation in healthy adults. She is the group leader of the respiratory clinical trials unit at Mater Research, and the program lead for the chronic and integrated care program at Mater Research. Lucy has a proven track record in collaborative and translational research. She is currently a consultant on 2 peer reviewed external grants totalling $1,306,000, including one involving biobanked samples, and is a chief investigator on a 2021 Ideas grant and a 2021 MRFF grant totalling more than $3 million dollars. Biological Sciences, Biomedical and Clinical Sciences, Cardiovascular medicine and haematology, Clinical sciences, Infectious diseases, Microbiology, Respiratory diseases

[2026] The worldwide puzzle of bronchiectasis etiology in adults [2026] Management of Adult Bronchiectasis: An American College of Chest Physicians Clinical Practice Guideline [2026] Benralizumab in bronchiectasis: results from the phase 3 MAHALE study [2026] Comorbid diabetes disease severity and microbial changes in patients with bronchiectasis: a combined analysis of data from the EMBARC, EMBARC-India, Australian, and BE-China registries [2026] METABOLIC SYNDROME IS ASSOCIATED WITH WORSE ASTHMA CONTROL: ANALYSIS FROM THE AUSTRALIAN SEVERE ASTHMA REGISTRY [2026] INCIDENCE OF TRIKAFTA INDUCED TRANSAMINASE DERANGEMENT IN A QUEENSLAND COHORT OF CYSTIC FIBROSIS PATIENTS [2026] RESPIRATORY AND EMERGENCY DEPARTMENT COLLABORATION IMPROVES EMERGENCY DEPARTMENT ASTHMA DISCHARGE CARE [2026] Polyso